BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND FLT4, FLT41, 2324, ENSG00000037280, P35916, VEGFR3, PCL AND Prognosis
69 results:

  • 1. Clinical and cytogenetic characteristics of primary and secondary plasma cell leukemia under the new IMWG definition criteria: a retrospective study.
    Guan J; Ma J; Chen B
    Hematology; 2023 Dec; 28(1):2254556. PubMed ID: 37732631
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. [Clinical Characteristics and Survival Analysis of Patients with Plasma Cell leukemia].
    Wang SF; Qin XQ; Guo QH; Wang JY; Ma YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):693-698. PubMed ID: 37356928
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Identification of signature genes and drug candidates for primary plasma cell leukemia: An integrated system biology approach.
    Chaudhary RK; Patil P; Ananthesh L; Gowdru Srinivasa M; Mateti UV; Shetty V; Khanal P
    Comput Biol Med; 2023 Aug; 162():107090. PubMed ID: 37295388
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Complete response following treatment of plasma cell leukemia with venetoclax and dexamethasone: A case report.
    Vo K; Guan T; Banerjee R; Lo M; Young R; Shah N
    J Oncol Pharm Pract; 2022 Jul; 28(5):1244-1248. PubMed ID: 35084252
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage.
    Fernández de Larrea C; Kyle R; Rosiñol L; Paiva B; Engelhardt M; Usmani S; Caers J; Gonsalves W; Schjesvold F; Merlini G; Lentzch S; Ocio E; Garderet L; Moreau P; Sonneveld P; Badros A; Gahrton G; Goldschmidt H; Tuchman S; Einsele H; Durie B; Wirk B; Musto P; Hayden P; Kaiser M; Miguel JS; Bladé J; Rajkumar SV; Mateos MV
    Blood Cancer J; 2021 Dec; 11(12):192. PubMed ID: 34857730
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia.
    Bezdekova R; Jelinek T; Kralova R; Stork M; Polackova P; Vsianska P; Brozova L; Jarkovsky J; Almasi M; Boichuk I; Knechtova Z; Penka M; Pour L; Sevcikova S; Hajek R; Rihova L
    Br J Haematol; 2021 Oct; 195(1):95-107. PubMed ID: 34500493
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Downregulation of ITGA6 confers to the invasion of multiple myeloma and promotes progression to plasma cell leukaemia.
    Song S; Zhang J; Su Q; Zhang W; Jiang Y; Fan G; Qian C; Li B; Zhuang W
    Br J Cancer; 2021 May; 124(11):1843-1853. PubMed ID: 33785876
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia.
    Li C; Cao W; Que Y; Wang Q; Xiao Y; Gu C; Wang D; Wang J; Jiang L; Xu H; Xu J; Zhou X; Hong Z; Wang N; Huang L; Zhang S; Chen L; Mao X; Xiao M; Zhang W; Meng L; Cao Y; Zhang T; Li J; Zhou J
    Clin Transl Med; 2021 Mar; 11(3):e346. PubMed ID: 33784005
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. A clinical perspective on plasma cell leukemia; current status and future directions.
    Tuazon SA; Holmberg LA; Nadeem O; Richardson PG
    Blood Cancer J; 2021 Feb; 11(2):23. PubMed ID: 33563906
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Successful upfront cord blood transplantation for plasma cell leukemia in the first complete response after daratumumab therapy.
    Ueno T; Sugio Y; Ohta T; Uehara Y; Ohno Y
    Int J Hematol; 2021 Jun; 113(6):941-944. PubMed ID: 33483877
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma.
    Oliva S; De Paoli L; Ruggeri M; Caltagirone S; Troia R; Oddolo D; D'Agostino M; Gilestro M; Mina R; Saraci E; Margiotta Casaluci G; Genuardi E; Bringhen S; Boccadoro M; Omedé P
    Ann Hematol; 2021 Feb; 100(2):437-443. PubMed ID: 33392702
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. [prognosis and Genetic Characteristics of Patients with Plasma Cell leukemia].
    Wu YL; Wang N; Yan YZ; Yuan LJ; Wang LL; Li HH; Li M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1804-1810. PubMed ID: 33283702
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Primary plasma cell leukaemia in a 39-year-old man.
    Kasinathan G
    BMJ Case Rep; 2020 Jul; 13(7):. PubMed ID: 32709663
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. [Treatment of early relapsed plasma cells leukemia after unrelated bone marrow transplant with KRD (carfilzomib, lenalidomide and dexamethasone): a case report.].
    Palazzo G
    Recenti Prog Med; 2020 Mar; 111(3):160-166. PubMed ID: 32157264
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. [A primitive plasma cell leukemia with immunoglobulin (Ig) E].
    Rachidi M; Lazarian G; Letestu R; Lusina D; Desbene C; Vidal V; Eclache V; Baran-Marszak F; Cymbalista F; Fleury C
    Ann Biol Clin (Paris); 2019 Oct; 77(5):557-561. PubMed ID: 31512579
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Plasma Cell Leukaemia: A Rare Yet Aggressive Plasma Cell Dyscrasia With A Very Poor Response To Conventional Therapy.
    Khan N; Raza SS; Khan UI; Hafez I; Abdullah MA; Hassan M; Rukh Hijaz AS; Hussain AK; Nadeem MD
    J Ayub Med Coll Abbottabad; 2019; 31(2):272-275. PubMed ID: 31094130
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Plasma Cell leukemia: Definition, Presentation, and Treatment.
    Gundesen MT; Lund T; Moeller HEH; Abildgaard N
    Curr Oncol Rep; 2019 Jan; 21(1):8. PubMed ID: 30689121
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. [Retrospective study of 25 cases of pulmonary mucormycosis in acute leukaemia].
    Caillot D; Legouge C; Lafon I; Ferrant E; Pagès PB; Plocque A; Estivalet L; Valot S; Dalle F; Abou Hanna H; Chretien ML
    Rev Mal Respir; 2018 Apr; 35(4):452-464. PubMed ID: 29754839
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia.
    Zatula A; Dikic A; Mulder C; Sharma A; Vågbø CB; Sousa MML; Waage A; Slupphaug G
    Oncotarget; 2017 Mar; 8(12):19427-19442. PubMed ID: 28038447
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease.
    Potratz J; Tillmanns A; Berning P; Korsching E; Schaefer C; Lechtape B; Schleithoff C; Unland R; Schäfer KL; Müller-Tidow C; Jürgens H; Dirksen U
    Mol Oncol; 2016 May; 10(5):677-92. PubMed ID: 26739507
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 4.